Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Cantor Fitzgerald
US Army
McKesson
Fuji
Citi
Novartis
Federal Trade Commission
UBS
Boehringer Ingelheim

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,081,249

« Back to Dashboard

Summary for Patent: 7,081,249
Title:Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Abstract:The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Inventor(s): Sanders; Steven W. (Salt Lake City, UT), Ebert; Charles D. (Salt Lake City, UT)
Assignee: Watson Laboratories, Inc. (Salt Lake City, UT)
Application Number:10/731,039
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,081,249

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE ➤ Sign Up
Allergan Sales Llc OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 OTC Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,081,249

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,743,441 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
7,081,251 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
7,081,252 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
7,179,483 Compositions and methods for transdermal oxybutynin therapy ➤ Sign Up
8,241,662 Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy ➤ Sign Up
7,087,241 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
7,029,694 Compositions and methods for transdermal oxybutynin therapy ➤ Sign Up
7,081,250 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,081,249

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 488233 ➤ Sign Up
Australia 2001253782 ➤ Sign Up
Australia 2003287377 ➤ Sign Up
Australia 2003294239 ➤ Sign Up
Australia 2010200418 ➤ Sign Up
Australia 2012216593 ➤ Sign Up
Australia 5378201 ➤ Sign Up
Brazil 0110381 ➤ Sign Up
Brazil 0315867 ➤ Sign Up
Canada 2406064 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
Harvard Business School
Healthtrust
US Department of Justice
US Army
QuintilesIMS
Express Scripts
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot